Acura Pharmaceuticals, Inc. · OTC:ACUR
Acura Pharmaceuticals — Investor Presentation (September 2015)
23 slides from Acura Pharmaceuticals's investor presentation, Sep 28, 2015
Slide 1: Fall 2015 Abuse Deterrent Specialty Pharmaceuticals
CONFIDENTIAL Nasdaq: ACUR Fall 2015 Abuse Deterrent Specialty Pharmaceuticals
Slide 2: General Caution Regarding Forward Looking Statements
Nasdaq: ACUR General Caution Regarding Forward Looking Statements Certain statements in this presentation constitute “forward - looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 . Such forwarding - looking statements involve known and unknown risks, uncer
Slide 3: Company Overview
Nasdaq: ACUR Company Overview Nasdaq: ACUR 3
Slide 4: Management, Board and Ownership
Nasdaq: ACUR Management, Board and Ownership » Key Management ▪ Bob Jones, President & CEO, Director (30+ years in pharmaceuticals) ▪ Peter Clemens, Sr. VP & CFO (25+ years in pharmaceuticals ) ▪ Al Brzeczko, PhD, Chief Scientific Officer (25+ years in pharmaceuticals ) » Board of Directors (non - m
Slide 5: Abuse of Prescription Opioids
Nasdaq: ACUR Abuse of Prescription Opioids Opioid Analgesics Morphine Hydrocodone (Vicodin®) Oxycodone (Percocet®, OxyContin®) etc. Moderate to Severe Pain US’s largest prescribed drug category Acute vs Chronic Immediate vs Extended Release Euphoria Over Ingestion Snorting Injection Tolerance, Depen
Slide 6: Abuse Deterrent Opioids – An Unmet Need
Nasdaq: ACUR Abuse Deterrent Opioids – An Unmet Need 2003 - FDA calls for industry to develop abuse deterrent formulations 2005 - Prescription opioid abuse described as “epidemic” - Joseph Califano , National Center for Addiction and Substance Abuse 2015 - Prescription drug abuse is the Nation's fas
Slide 7: Immediate-Release Opioid Abuse is Most Prevalent
Nasdaq: ACUR 0 5 10 15 20 25 Demerol® Methadone Tramadol Morphine OxyContin® Codeine Hydrocodone Percocet®, Percodan® & Tylox® Darvocet®, Darvon® & Tylenol® w/Codeine Vicodin®, Lortab®, & Lorcet® Lifetime abusers 12 and older (millions) Immediate - Release Opioid Abuse is Most Prevalent Source: SAMH
Slide 8: FDA Incentivizes Oral Abuse Deterrence in Immediate-release Formulations
Nasdaq: ACUR FDA Incentivizes Oral Abuse Deterrence in Immediate - release Formulations • April 2015 – FDA Guidance “Abuse Deterrent Opioid – Evaluation and Labeling” • Immediate - release opioids containing acetaminophen (APAP) • Predominately abused by the oral route • Addressing nasal abuse may n
Slide 9: Acura's Abuse Deterrent Technology Platforms
Nasdaq: ACUR Acura’s Abuse Deterrent Technology Platforms –; Opioid Abuse – Oral, Snorting and Injection –; Accidental overdose of NTI drugs –; Immediate - Release Segment –; $2.7 billion addressable segment with pricing leverage –; Partnership Opportunities –; Issued US Patent to 2033 –; Pseudoephe
Slide 10: Route of Abuse Addressed by Company Technology
Nasdaq: ACUR Route of Abuse Addressed Company Technology Oral* Nasal IV Acura Limitx™ *; *; *; Acura Aversion® *; *; Purdue unknown *; *; Grunenthal Intac ™ IR *; *; Atlantic SMART/Script™ *; *; KemPharm Prodrug 1 *; *; Signature Prodrug *; *; Pisgah Acid soluble salts *; *; Limitx™ is at the forefr
Slide 11: The Limitx Technology
Nasdaq: ACUR Illustration The Limitx™ Technology Product Formulation • Micro - particles containing the opioid active ingredient • Functional tablet matrix of other ingredients Oral Abuse Deterrence • Tablet matrix acts synergistically with the micro - particle ingredients to retard the release of m
Slide 12: Limitx Proof of Concept
Nasdaq: ACUR Limitx™ Proof of Concept • .055N HCl simulated stomach acid • Blue line - Single Limitx™ tablet releases 100% in ~20 minutes • Red line – 8 Limitx™ tablets release 66% in ~120 minutes • Green line – 1 Dilaudid ® tablet releases 100% in ~60 minutes Nasdaq: ACUR 12
Slide 13: Limitx Benefits
Nasdaq: ACUR Limitx™ Benefits Nasdaq: ACUR As identified by o pioid prescribers 13
Slide 14: Immediate Release Opioids Market Opportunity
Nasdaq: ACUR Immediate Release Opioids Market Opportunity 2014 Addressable Market (millions) Immediate - release Opioid Reference Brand(s) TRx Tablets Dollars Price/ Tab* Hydrocodone/APAP Vicodin, Norco 117.5 6,883 984 .14 Oxycodone/APAP Percocet 35.5 2,206 994 .45 Oxycodone Roxicodone 14.8 1,672 48
Slide 15: Limitx Near Term Activities
Nasdaq: ACUR Limitx™ Near Term Activities • 4Q - 2015 • Submit an Investigational New Drug application to the FDA for Hydromorphone • Initiate a pilot p harmacokinetic study for Hydromorphone • Initiate development Hydrocodone micro - particle • 1H - 2016 • Pilot pharmacokinetic study for Hydromorph
Slide 16: Marketed Product Opportunities
Nasdaq: ACUR Marketed Product Opportunities • Aversion® Opioids Analgesic • Oxaydo ™ FDA approved • Licensed worldwide to Egalet Corp. • Product launched in the US in September 2015 • Supported by 50 sales representatives • Differentiated abuse deterrent label (snorting) • 1.6 billion tablet address
Slide 17: Oxaydo – Egalet Partnership
Nasdaq: ACUR • Egalet has US and EU Operations • Extended - release abuse deterrent formulations in development • Right of first negotiation for a Limitx™ oxycodone product Financial Terms • $5.0 million upfront payment • $2.5 million upon first US product shipment • $ 12.5 million one time mileston
Slide 18: Impede Technology/Nexafed Franchise
Nasdaq: ACUR Impede® Technology/Nexafed® Franchise • Chemical conversion of pseudoephedrine (PSE) from cold products into methamphetamine • Dangerous, toxic process requires costly clean - up and creates child endangerment • Highly addictive – no pharmaceutical treatment • 1.2 million people in the
Slide 19: Impede – Expansion/Partnering Opportunities
Nasdaq: ACUR $0 $20 $40 $60 $80 2014 US ex - Factory 1 Sales ($340 Million) PSE/Cetirizine* PSE/ Loratadine * PSE 30mg PSE 120mg* PSE/Ibuprofen PSE/fexofenadine* Impede® - Expansion/Partnering Opportunities *12 Hour Extended - Release • Higher value targets in extended - release segment • Move to be
Slide 20: Intellectual Property and Financial Information
Nasdaq: ACUR Intellectual Property and Financial Information 20
Slide 21: Intellectual Property Position
Nasdaq: ACUR • Limitx™ Technology US issued patent expires 2033 • 1 U.S. patent issued • Aversion® Technology US issued patents expire 2023 to 2025 • 6 U.S. patents issued • US Generic market entry January 2022 • Patents issued in selected foreign jurisdictions • Impede® Technology US issued patent
Slide 22: Selected Financial Information
Nasdaq: ACUR Selected Financial Information $ Millions Cash, Cash Equivalents and Marketable Securities $15.2 Debt (60 month term @ 8.35% with interest only thru March, 2015 and principal & interest to December 2018) $8.7 Shares Outstanding Millions Total Common Shares Outstanding 11.801 Shares Held
Slide 23: Acura Pharmaceuticals, Inc.
CONFIDENTIAL Nasdaq: ACUR Acura Pharmaceuticals, Inc. 616 N. North Court, Suite 120 Palatine, IL 60067 (847) 705 - 7709 www.AcuraPharm.com www.Nexafed.com www.Oxaydo.com
Acura Pharmaceuticals — Investor Presentation (September 2015) on 6ix